Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas

Neuro-Oncology

Volumn 14, Issue 9, 2012, Pages 1163-1170

  Karajannis, Matthias A ^a   Legault, Geneviève ^a   Hagiwara, Mari ^a   Ballas, Marc S ^a   Brown, Krysten ^a   Nusbaum, Annette O ^a   Hochman, Tsivia ^a   Goldberg, Judith D ^a   Koch, Kevin M ^b   Golfinos, John G ^a   Thomas Roland, J ^a   Allen, Jeffrey C ^a  

^a NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Acoustic neuroma; Lapatinib; Neurofibromatosis type 2; Phase II trial; Vestibular schwannoma

Indexed keywords

BEVACIZUMAB; LAPATINIB;

ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; ARTICLE; AUDIOGRAPHY; CARDIOTOXICITY; CHILD; CLINICAL ARTICLE; DIARRHEA; FATIGUE; FEMALE; HEADACHE; HEARING; HUMAN; HUMAN TISSUE; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 2; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROGRESSIVE VESTIBULAR SCHWANNOMA; PURE TONE AUDIOMETRY; RASH; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WORD RECOGNITION; WOUND HEALING IMPAIRMENT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; SURVIVAL RATE; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84867528840     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos146     Document Type: Article

References (30)

1. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. Embo J. 2004;23(8):1739-1748.
2. Takahashi K, Suzuki K. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp Cell Res. 1996;226(1):214-222.
3. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J Cell Biol. 2007;177(5):893-903.
4. Doherty JK, Ongkeko W, Crawley B, Andalibi A, Ryan AF. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy. Otol Neurotol. 2008;29(1):50-57.
5. Evans DG, Kalamarides M, Hunter-Schaedle K, et al. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. Clin Cancer Res. 2009;15(16):5032-5039.
6. Ammoun S, Cunliffe CH, Allen JC, et al. ErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma. Neuro Oncol. 2010;12(8):834-843.
7. Xia W, Mullin RJ, Keith BR, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21(41):6255-6263.
8. Dhillon S, Wagstaff AJ. Lapatinib. Drugs. 2007;67(14):2101-2108. discussion 2109-2110.
9. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278(1):51-57.
10. Stangerup SE, Caye-Thomasen P, Tos M, Thomsen J. The natural history of vestibular schwannoma. Otol Neurotol. 2006;27(4):547-552.
11. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
12. Fouladi M, Stewart CF, Blaney SM, et al. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010;28(27):4221-4227.
13. Harris GJ, Plotkin SR, Maccollin M, et al. Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurg. 2008;62(6):1314-1319.
14. Plotkin SR, Halpin C, Blakeley JO, et al. Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009;93(1):61-77.
15. Blakeley JO, Evans DG, Adler J, et al. Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2011;158A(1):24-41.
16. Bai F, Freeman BB, 3rd, Fraga CH, Fouladi M, Stewart CF. Determinationof lapatinib (GW572016) in human plasma by liquid chromatography electrospray tandem mass spectrometry (LC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2006;831(1-2):169-175.
17. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327-332.
18. Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med. 1992;84(304):603-618.
19. Mautner VF, Tatagiba M, Lindenau M, et al. Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. AJR Am J Roentgenol. 1995;165(4):951-955.
20. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43(4):289-294.
21. Plotkin SR, Stemmer-Rachamimov AO, Barker FG II, et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009;361(4):358-367.
22. Mautner VF, Nguyen R, Kutta H, et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 2010;12(1):14-18.
23. Mautner VF, Nguyen R, Knecht R, Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol. 2010;21(11):2294-2295.
24. Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG, 2nd. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010;31(7):1135-1143.
25. Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211-217.
26. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008;26(12):1993-1999.
27. Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-1459.
28. Taskar KS, Rudraraju V, Mittapalli RK, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2011;29(3):770-781.
29. Tortora G, Ciardiello F, Gasparini G. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nature Clin Prac. 2008;5(9):521-530.
30. Rugo HS, Jo Chien A, Franco SX, et al. A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancer. [published online ahead of print December 24, 2011] Breast Cancer Res Treat. doi:10.1007/s10549-011-1918-z.